Other Clinical Trial - Preventing Urinary Tract Infections With E. Coli

Status Recruiting

Clinical Trial Summary

Urinary tract infections (UTIs) account for 5-14% of pediatric emergency department visits annually. At the moment, up to one third of children suffering of acute (UTI) will have a new infection and there is a lack of effective methods for preventing secondary UTIs in young children. Majority of UTIs in children are caused by intestinal bacteria of the patient, mainly E. coli that colonizes gut of the patient. E. coli Nissle is a probiotic strain that has been used successfully for treating acute gastrointestinal infections in children. The strain has also been proved to be safe for infants and young children. E. coli Nissle could be a potential solution for preventing recurrent urinary tract infections in children as it competes with pathogenic bacteria that usually cause UTIs in children. The aim of this study is to evaluate efficacy of E. coli Nissle strain in secondary prevention of urinary tract infections in young children.

Clinical Trial Description

In order to asses efficacy of E. coli Nissle strain in prevention of recurrent UTIs in children, we aim to conduct randomized, placebo controlled and double blinded clinical trial. We are going to recruit children who are suffering the first urinary tract infection of their life. The UTI will be treated by normal clinical recommendations decided by treating physician. Intervention will start on the day following the last day of the antimicrobial course. The intervention will last for 15 days and the study participants will receive either intervention drug or placebo. Intervention drug contains 10 E8 CFU/ml of E. coli Nissle strain and will be administered as dose of 1 ml of oral suspension once daily for children aged under one year and twice daily for children aged more than one year. The study patients will be monitored by monthly electronic surveys for six months after the intervention in order to measure proportion of the children who will have a new UTI during the follow up. We are also going to record possible adverse effects in both study groups. Also use of antimicrobial medication due to any reason will be recorded. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04608851
Study type	Interventional
Source	University of Oulu
Contact	Terhi Tapiainen
Phone	+35883155185
Email	terhi.tapiainen@oulu.fi
Status	Recruiting
Phase	Phase 4
Start date	January 18, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02197416` - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children	Phase 3
Completed	`NCT02550717` - Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
Recruiting	`NCT06025526` - Effectiveness of the Aktivplan Digital Intervention (ACTIVE-CaRe Pilot)	N/A
Completed	`NCT03234023` - Secondary PRevention in Cardiovascular Disease by a Nursing Guided Program (SPRING)	N/A
Completed	`NCT02239120` - Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)	Phase 3
Completed	`NCT04821518` - The Use of Samsung Health and ECG M-Trace Base II Applications in the Secondary Prevention After Stroke
Recruiting	`NCT04121702` - Outpatient Cardiac Tele-Rehabilitation in a Public Sports Center	N/A
Active, not recruiting	`NCT04893447` - Suicide Prevention Among Recipients of Care	N/A
Recruiting	`NCT06258928` - Early Mobilisation of the Distal Radius Fracture
Not yet recruiting	`NCT03269708` - Improving Cardiac Secondary Prevention	N/A
Active, not recruiting	`NCT05426863` - Domestic Violence Intervention to Reduce Psychological Distress and Violence Among Women Experiencing IPV in Nepal	N/A
Recruiting	`NCT05942794` - Identification of Oral Lesions Through an Autofluorescence System	N/A
Recruiting	`NCT03186729` - Study of Antithrombotic Treatment After IntraCerebral Haemorrhage	Phase 4
Completed	`NCT02156778` - Post-Stroke Disease Management - Stroke Card	N/A
Recruiting	`NCT06243133` - Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis	Phase 4
Completed	`NCT01915043` - Improving Adherence Healthy Lifestyle With a Smartphone Application Based After Surgery in Cancer Patients	N/A
Completed	`NCT00643019` - Project Sexual Awareness for Everyone (SAFE)	Phase 3
Recruiting	`NCT03065543` - Hyperlipidemia Therapy TERCET Zabrze Registry	N/A
Completed	`NCT04199663` - Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction
Recruiting	`NCT05542719` - Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Preventing Urinary Tract Infections With E. Coli Nissle: — FinNissle

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms